68-1

26/98

strategies. Psychiatry Clin Neurosci. 2019; 73: 526-40.12) Cavanagh JT, Van Beck M, Muir W, Blackwood DH: Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry. 2002; 180: 320-6.13) Kanba S, Kato T, Terao T, Yamada K: Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013; 67: 285-300.14) Kato T, Ishigooka J, Miyajima M, et al: Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci. 2020; 74: 635-44.15) Calabrese JR, Sanchez R, Jin N, et al: Efficacy and Safety of Aripiprazole Once-Monthly in the Mainte-nance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized With-drawal Study. J Clin Psychiatry. 2017; 78: 324-31.16) Patorno E, Huybrechts KF, Bateman BT, et al: Lithium Use in Pregnancy and the Risk of Cardiac Malforma-tions. N Engl J Med. 2017; 376: 2245-54.17) Miklowitz DJ, Efthimiou O, Furukawa TA, et al: Adjunc-tive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78: 141-50.18) Kato T: Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci. 2007; 61: 3-19.19) Aldinger F, Schulze TG: Environmental factors, life events, and trauma in the course of bipolar disorder. Psychiatry Clin Neurosci. 2017; 71: 6-17.20) Ikeda M, Saito T, Kondo K, Iwata N: Genome-wide association studies of bipolar disorder: A systematic review of recent findings and their clinical implica-tions. Psychiatry Clin Neurosci. 2018; 72: 52-63.21) Mullins N, Forstner AJ, O’Connell KS, et al: Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the under-24lying biology. Nat Genet. 2021; 53: 817-29.22) Ikeda M, Takahashi A, Kamatani Y, et al: A genome-wide association study identifies two novel suscepti-bility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry. 2017.23) Nishioka M, Kazuno AA, Nakamura T, et al: System-atic analysis of exonic germline and postzygotic de novo mutations in bipolar disorder. Nat Commun. 2021; 12: 3750.24) Kato T: Neurobiological basis of bipolar disorder: Mito-chondrial dysfunction hypothesis and beyond. Schizophr Res. 2017; 187: 62-6.25) Kasahara T, Takata A, Kato TM, et al: Depression-like episodes in mice harboring mtDNA deletions in para-ventricular thalamus. Mol Psychiatry. 2016; 21: 39-48.26) Hsu DT, Kirouac GJ, Zubieta JK, Bhatnagar S: Contri-butions of the paraventricular thalamic nucleus in the regulation of stress, motivation, and mood. Front Behav Neurosci. 2014; 8: 73.27) Kato TM, Kubota-Sakashita M, Fujimori-Tonou N, et al: Ant1 mutant mice bridge the mitochondrial and serotonergic dysfunctions in bipolar disorder. Mol Psychiatry. 2018; 23: 2039-49.28) Mertens J, Wang QW, Kim Y, et al: Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015; 527: 95-9.29) Horisawa T, Ishiyama T, Ono M, Ishibashi T, Taiji M: Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradi-ography. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 132-7.30) Sharpley AL, Williams C, Holder AA, et al: A phase 2a randomised, double-blind, placebo-controlled, paral-lel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psycho-pharmacology (Berl). 2020; 237: 3773-82.